The role of intravenous iron in anemia management and transfusion avoidance. (abre una nueva ventana)

Auerbach M, Goodnough LT, Picard D, Maniatis A.

Fuente‎: Transfusion 2008;48(5):988-1000.

Indexado en‎: PubMed 18346021

DOI‎: 10.1111/j.1537-2995.2007.01633.x

https://www.ncbi.nlm.nih.gov/pubmed/18346021 (abre una nueva ventana)

The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancer. (abre una nueva ventana)

Djavan B, Laze J, Eckersberger E, Finkelstein J, Agalliu I, Lepor H.

Fuente‎: BJU Int 2011;108(10):1582-7.

Indexado en‎: PubMed 21443653

DOI‎: 10.1111/j.1464-410X.2011.10173.x

https://www.ncbi.nlm.nih.gov/pubmed/21443653 (abre una nueva ventana)

The preoperative use of erythropoietin stimulating proteins prior to radical prostatectomy is not associated with increased cardiovascular or thromboembolic morbidity or mortality. (abre una nueva ventana)

Lepor H, Lipkin M, Slova D.

Fuente‎: Urology 2010;75(6):1424-8.

Indexado en‎: PubMed 20513505

DOI‎: 10.1016/j.urology.2009.06.095

https://www.ncbi.nlm.nih.gov/pubmed/20513505 (abre una nueva ventana)

Comparison of two different doses of preoperative recombinant erythropoietin in men undergoing radical retropubic prostatectomy. (abre una nueva ventana)

Nieder AM, Rosenblum N, Lepor H.

Fuente‎: Urology 2001;57(4):737-41.

Indexado en‎: PubMed 11306393

https://www.ncbi.nlm.nih.gov/pubmed/11306393 (abre una nueva ventana)